Research brief
Intracerebral haemorrhage (ICH) presents a severe challenge with few treatment options and high mortality. Recent research has turned to glimepiride, a drug known for its protective effects in other brain disorders, to see if it can reduce brain injury after ICH. In a study with mice, glimepiride showed promise by preserving the blood-brain barrier, reducing neuroinflammation, and improving neurological function. These results suggest glimepiride could be a potential treatment for ICH, though its effectiveness in humans remains to be confirmed.
Key points
- Glimepiride may help protect the blood-brain barrier in ICH.
- The drug reduced brain inflammation in mice.
- Neurological functions improved with glimepiride treatment.
Preserving the Blood-Brain Barrier
The study examined how glimepiride affects the blood-brain barrier in mice with intracerebral haemorrhage. Mice given glimepiride showed higher levels of proteins ZO-1 and occludin, which are essential for keeping the barrier intact. There was also a notable decrease in the leakage of albumin and Evans blue dye into brain tissue, suggesting the drug effectively maintained the barrier's function.
Easing Neuroinflammation
Neuroinflammation plays a significant role in brain injury after ICH. The study found that glimepiride treatment reduced levels of inflammatory markers like Iba-1 and myeloperoxidase in the brain. This indicates that the drug has anti-inflammatory properties, which may contribute to its protective effects on the brain.
Enhancing Neurological Recovery
Mice treated with glimepiride showed better results in neurological tests, such as the corner turn test and modified Garcia test. These improvements were linked to a decrease in brain swelling and haematoma size. The study also noted a reduction in neuronal cell death, as seen in changes to BCL-2 and BAX protein levels, further suggesting that glimepiride could aid recovery after ICH.
Discover more from Neurospan
Subscribe to get the latest posts sent to your email.
